Blog

Health Law News, Private Equity

Print PDF

Private Equity Deal Spotlight | Weekly Update

Posted on November 19, 2026 in Health Law News, Private Equity

Published by: Hall Render

Health care continues to drive private equity (“PE”) activity, creating opportunities for investors and traditional health care providers. Transactions in the health care space are especially complicated, layering health care regulatory and reimbursement considerations on top of a complex securities, antitrust, privacy and security framework.

Hall Render’s PE team of attorneys and advisors leverage the strength and depth of our bench to navigate and efficiently execute PE transactions. The summary below includes highlights of recent PE deals and legislative updates.

  • Lifecore Biomedical recently announced a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, assuming full achievement of performance milestones. Lifecore, headquartered in Chaska, MN, is a contract development and manufacturing organization specializing in sterile injectable pharmaceutical products. Webster Equity Partners, headquartered in Waltham, MA, is a middle-market PE firm focused exclusively on health care services companies. The transaction is expected to close at the end of the fourth quarter of 2026. 
  • Prairie Capital recently announced its partnership with executives Ankit Aggarwal and Jack Glerum to acquire Medefil, an FDA-approved pharmaceutical developer, manufacturer and marketer of prefilled syringe products for acute care markets. Medefil, headquartered in Glendale Heights, IL, was founded in 1998 and operates a U.S.-based, vertically integrated manufacturing facility. Prairie Capital plans to support the company’s growth through investments in personnel, new products, sales and marketing, technology, supply chain, infrastructure and add-on acquisitions. Prairie Capital is a private equity firm focused on helping high-potential, founder-owned companies become scalable platforms positioned for accelerated growth. 
  • Aphias Capital recently announced the close of its inaugural fund, Aphias Capital Fund I, with more than $1.05 billion in commitments. The fund exceeded its $900 million target. Aphias Capital, founded in 2025 and headquartered in San Francisco, CA, is a PE firm focused on health care services and essential services companies in the lower middle market. 
  • Everis Medical, backed by Shore Capital Partners, recently announced its combination with Hemostasis, LLC. The combined company will operate as Everis Medical and will offer a broader portfolio of products for sinus and nasal surgery, including repair and reconstruction, hemostasis, post-operative healing and infection management. Everis, headquartered in Kalamazoo, MI, is a medical device company focused on otolaryngology, head and neck surgery and related specialties. Shore Capital Partners, headquartered in Chicago, IL, invests in lower middle-market companies across health care and other industries. 
  • Ironleaf Capital recently announced its inaugural investment in Healthcare Control Systems, a health care technology company whose ORControl platform helps hospitals coordinate personnel, clinical resources and workflows in real time. Healthcare Control Systems’ technology is used by hospitals and health systems in the United States and Europe. Ironleaf Capital, headquartered in New York, NY, is a technology-focused health care PE firm that invests in lower middle-market, privately held and founder-owned companies. 
  • Frazier Healthcare Partners recently announced the completion of its majority investment in ATUM, a bioengineering company that combines machine learning with gene design, protein optimization and cell line development. ATUM, headquartered in Newark, CA, provides end-to-end bioengineering solutions intended to shorten and reduce risk in drug development. Frazier Healthcare Partners, headquartered in Seattle, WA, is a PE firm focused exclusively on the health care industry. 

For questions or additional information on private equity matters, please contact:

Hall Render blog posts and articles are intended for informational purposes only. For ethical reasons, Hall Render attorneys cannot—outside of an attorney-client relationship—answer specific questions that would be legal advice.